Data completeness
2/8 — Basic
LAMIVUDINE AND STAVUDINE (lamivudine; stavudine) by Hetero is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMIVUDINE AND STAVUDINE is a fixed-dose oral combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for HIV-1 infection in adults and pediatric patients weighing at least 6 kg. The combination works by inhibiting HIV-1 reverse transcriptase, reducing viral replication and slowing disease progression. This is a pre-launch product from Hetero in a crowded antiretroviral therapy landscape.
Pre-Launch
Pre-launch status with no commercial data indicates early-stage commercialization opportunity but uncertain market penetration given high competitive saturation.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE AND STAVUDINE at Hetero? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.